Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy
qimono / Pixabay

Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy

According to a story from physiciansweekly.com, a recent report from the Institute for Clinical and Economic Review (ICER) suggests that, pending more data about overall price and longterm success rates,…

Continue Reading Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy

Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Myasthenia Gravis (MG) is a progressive autoimmune disorder which results in the weakening of muscles. Most people with the condition are able to manage their symptoms with treatment and have…

Continue Reading Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online
Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial
Aymanejed / Pixabay

Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial

According to a story from drugs.com, the biopharmaceutical company Catabasis pharmaceuticals recently provided updates on the status of its Phase 3 clinical trial testing its investigational therapy CAT-1004, also known…

Continue Reading Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial
New Research Seeks to Learn More About Bronchiectasis to Guide Treatment
mwooten / Pixabay

New Research Seeks to Learn More About Bronchiectasis to Guide Treatment

A new bronchiectasis research study was added to the clinicaltrials.gov website on New Years Day. This observational study, called the BRIDGE Study (Bronchiectasis Research Involving Databases, Genomics, and Endotyping) is…

Continue Reading New Research Seeks to Learn More About Bronchiectasis to Guide Treatment